| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8,3 M € | +1.5% | 8,2 M € | +6.3% | 7,7 M € | +26.3% | 6,1 M € | -20.8% | 7,7 M € | -17.8% | 9,4 M € | -8.5% | 10,2 M € | -5.9% | 10,9 M € | +25.6% | 8,7 M € | +12.2% | 7,7 M € | +31.0% | 5,9 M € | +101.0% | 2,9 M € | +478.8% | 507,3 k € | |
| EBITDA | 1,3 M € | -16.5% | 1,5 M € | +7.4% | 1,4 M € | +94.3% | 726,9 k € | -51.1% | 1,5 M € | -10.8% | 1,7 M € | +6.8% | 1,6 M € | +22.4% | 1,3 M € | +49.7% | 852,4 k € | +35.7% | 628,1 k € | +36.6% | 459,8 k € | +126.1% | 203,3 k € | +379.4% | 42,4 k € | |
| Operating profit | 1,2 M € | -18.6% | 1,5 M € | +7.6% | 1,4 M € | +95.7% | 715,2 k € | -51.7% | 1,5 M € | -10.2% | 1,6 M € | +6.8% | 1,5 M € | +24.3% | 1,2 M € | +51.9% | 818,7 k € | +40.4% | 583,1 k € | +33.5% | 436,8 k € | +124.1% | 194,9 k € | +387.3% | 40,0 k € | |
| Profit/loss | 985,7 k € | -21.5% | 1,3 M € | +7.7% | 1,2 M € | +113.0% | 547,2 k € | -49.5% | 1,1 M € | -9.9% | 1,2 M € | +17.5% | 1,0 M € | +27.4% | 802,5 k € | +69.3% | 474,0 k € | +64.2% | 288,7 k € | +41.2% | 204,5 k € | +152.3% | 81,0 k € | +435.4% | 15,1 k € | |
| Equity | 9,1 M € | +12.1% | 8,2 M € | +18.2% | 6,9 M € | +20.3% | 5,7 M € | +10.5% | 5,2 M € | +26.4% | 4,1 M € | +41.3% | 2,9 M € | +54.3% | 1,9 M € | +74.2% | 1,1 M € | +78.0% | 607,9 k € | +90.5% | 319,2 k € | +178.2% | 114,7 k € | +240.6% | 33,7 k € | |
| Total assets | 11,0 M € | +8.0% | 10,2 M € | +15.0% | 8,8 M € | +21.3% | 7,3 M € | +8.8% | 6,7 M € | +25.2% | 5,3 M € | -22.7% | 6,9 M € | +25.7% | 5,5 M € | +35.3% | 4,1 M € | +11.2% | 3,7 M € | +12.9% | 3,2 M € | +251.0% | 921,5 k € | +1.2% | 910,4 k € | |
| Cash | — | — | — | — | — | — | — | — | — | 98,1 k € | +848.1% | 10,3 k € | -68.3% | 32,6 k € | +34.2% | 24,3 k € | ||||||||||
| Debts | 1,6 M € | -8.7% | 1,8 M € | +1.0% | 1,8 M € | +22.5% | 1,4 M € | +7.0% | 1,4 M € | +29.5% | 1,0 M € | -66.6% | 3,1 M € | +39.7% | 2,2 M € | -7.5% | 2,4 M € | +15.3% | 2,1 M € | +4.5% | 2,0 M € | +706.8% | 248,9 k € | -67.4% | 763,4 k € | |
| Staff | 19,3 | 16,8 | 15,8 | 16,4 | 14,4 | 12,1 | 14 | 11,4 | 11,9 | 11,5 | 8,8 | 5,7 | 0,5 | |||||||||||||
Private limited company · Zaventem · incorporated on 28/06/2013 · 19,3 ETP
Private limited company profitable and well capitalised. Cash position rising (+848.1%).
Solid counterparty for a standard engagement.
Swedish Orphan Biovitrum (Belgium) is a Private limited company incorporated in 2013. Its main activity is: Management consultancy activities. Its registered office is in Zaventem. It employs on average 19,3 ETP workers (FTE).
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette